Fulcrum Therapeutics(FULC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The 20-milligram cohort of the PIONEER trial showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [5][12] - Total hemoglobin increased by more than 1 gram per deciliter after 12 weeks of treatment [5][21] - The safety profile of pociredir at the 20-milligram dose remains generally well-tolerated, with no treatment-related serious adverse events reported [18][81] Business Line Data and Key Metrics Changes - In the 20-milligram cohort, 58% of patients achieved HbF levels at or above 20%, which is historically associated with clinically meaningful protection [5][12] - There was a 34% reduction in lactate dehydrogenase (LDH) and a 40% reduction in indirect bilirubin at week 12, indicating reduced hemolysis [15] - The cohort experienced a 42% drop in reticulocytes, reflecting decreased bone marrow stress due to reduced hemolysis [16] Market Data and Key Metrics Changes - Sickle cell disease remains a debilitating condition affecting millions globally, with significant unmet medical needs despite advances in clinical care [7] - The expected vaso-occlusive crises (VOCs) based on baseline data was 16 events over 12 weeks, but only 6 events were observed in 5 patients during the treatment period [17] Company Strategy and Development Direction - The company plans to provide an update on the next trial design in Q2 2026 and aims to initiate a potential registration-enabling trial in the second half of 2026 [29] - Engagement with the European Medicines Agency is planned for mid-2026 to obtain protocol assistance and feedback on the next trial design [29] - The company is activating sites for an open-label extension study for PIONEER patients to evaluate the longer-term safety and durability of response of pociredir [29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly impact the treatment of sickle cell disease, especially given the limitations of current therapies like hydroxyurea [22][86] - The unmet need for effective treatments in sickle cell disease is highlighted, especially following the withdrawal of certain therapies and the limited uptake of others [86] - The company believes it has a two-year head start over competitors in the market for fetal hemoglobin-inducing agents [78] Other Important Information - The 20-milligram cohort data reinforces the belief that pociredir is demonstrating a biological profile expected from a best-in-class oral HbF inducer for sickle cell disease [6] - The trial design included a high degree of disease severity among participants, with a focus on patients with significant baseline VOCs [9] Q&A Session Summary Question: Can you provide additional insight into when VOCs occurred during the study? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [32][34] Question: How well does the 20-milligram cohort represent the population of sickle cell patients? - The 20-milligram cohort is believed to represent a middle slice of the global population, with more heterogeneity in haplotypes compared to previous cohorts [35][37] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, are expected to show more immediate effects, while total hemoglobin may take longer to reflect the full impact of HbF induction [40][44] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data supporting HbF induction and its association with improved clinical outcomes in sickle cell disease [49][50] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established therapy showing sustained disease-modifying effects, and many patients still experiencing severe events [86]